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was the number needed to treat (NNT). Due to lack of face-to-
face evidence on biologics, an indirect comparison of the trials
was conducted, applying the method proposed by Butcher.
RESULTS: Sixteen RCTs involving 7339 patients were identiﬁed.
The active treatment was adalimumab in 1 trial (n = 147),
alefacept in three trials (n = 1289), efalizumab in four trials
(n = 2444), etanercept in four trials (n = 1964) and inﬂiximab in
four trials (n = 1495). All trials were placebo controlled and the
primary follow-up time was 12 weeks. The primary outcome was
PASI75 criteria in all trials. To achieve PASI75, the number of
patients needed to treat (95% conﬁdence intervals) with adali-
mumab 40 mg/eow, alefacept 15 mg, efalizumab 1 mg/kg, etan-
ercept 2 ¥ 50 mg/week and inﬂiximab 5 mg/kg were 2.04 (1.54–
2.94), 5.00 (3.57–7.69), 3.85 (3.13–5.26), 2.27 (2.08–2.50) and
1.32 (1.25–1.39), respectively. Indirect comparisons of TNF-
alpha inhibitors and T-cell modulators yielded the odds ratios of
5.54 (3.65–8.42). CONCLUSION: All biologicals were superior
to placebo, alefacept with the highest and inﬂiximab with the
lowest NNT. TNF-alpha inhibitors were signiﬁcantly superior to
T-cell modulators.
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OBJECTIVE: To compare the effectiveness of Cortisporin and
Ciprodex therapies in the treatment of acute otitis externa (AOE)
in the Louisiana Medicaid population. METHODS: A retrospec-
tive analysis of Louisiana Medicaid data using paid claims from
January 1, 2004, to December 31, 2005, was conducted for
recipients aged 1–64 years. Recipients with an AOE medical
claim (index diagnosis) followed within ﬁve days by a claim for
Ciprodex or Cortisporin were identiﬁed. Any recipients with
dual therapy (deﬁned as greater than one antibiotic or otic
agent), concomitant infection, AOE diagnosis within 30 days
prior to index diagnosis, or other diagnosis warranting antibiotic
therapy within 30 days post index claim were excluded. Each
recipient’s medical and pharmacy claims for 30 days after the
index diagnosis were identiﬁed and evaluated for treatment
failure. Treatment failure was deﬁned as presence of an addi-
tional prescription claim for an antibiotic (oral or otic) or an
antibiotic-steroid combination with or without another medical
AOE claim. The two drug cohorts (Ciprodex and Cortisporin)
were matched using the greedy match technique. Effectiveness,
deﬁned as the proportion of failure patients in each cohort, was
analyzed using the binomial proportion test. RESULTS: The
population consisted predominately of females (55.66%), Cau-
casians (63.49%), and recipients from the New Orleans region
(34.02%). Forty-eight percent of the prescription claims were
written by pediatricians. Each matched cohort had 901 recipients
with average age 10.01 (SD = 6.50) years (Ciprodex), and 10.45
(SD = 7.27) years (Cortisporin). Before propensity score match-
ing, the respective failure rates for Cortisporin and Ciprodex
were 7.47% and 4.69% (p = 0.0009). Within the matched
cohorts, respective failure rates for Cortisporin and Ciprodex
were 6.88% and 4.77% (p = 0.056). CONCLUSION: In the
Louisiana Medicaid population, Cortisporin had a higher failure
rate than Ciprodex for AOE; after propensity score matching the
difference approached statistical signiﬁcance at the 0.05 alpha
level.
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OBJECTIVE: To classify published randomised controlled trials
(RCTs) regarding the comparative efﬁcacy and safety of topical
glaucoma treatment to identify where the evidence lies and the
gaps for future research. METHODS: A systematic search of
MEDLINE, EMBASE, Cochrane Central and conference pro-
ceedings for RCTs recruiting adults with primary open-angle
glaucoma (POAG) and/or ocular hypertension (OH) receiving
any topical medication or placebo. After double-data entry, the
characteristics were analysed with a focus on prostaglandin-
containing trials. RESULTS: We identiﬁed 510 RCTs. Mean
study duration was 15.2 weeks (SD 19.9), with 78% of studies
lasting less than three months. Grouping of studies by duration
and treatment showed that short-term efﬁcacy was available for
all treatments, but RCT evidence of longer-term safety (>12
months) was conﬁned to latanoprost (three trials) and timolol
maleate (two trials) in the monotherapy group and dorzolamide
and timolol in ﬁxed combination (one trial). The majority of
the study population (79.6%) was Caucasian. The data on
co-morbidity was sparse. Of prostaglandins, only latanoprost
reported hypertension as a sub-group. Latanoprost monotherapy
and latanoprost/timolol ﬁxed combination therapy had been
compared with the broadest range of alternative therapies.
Latanoprost alone had been compared with all other classes of
treatments. CONCLUSION: There are extensive RCT data
available for glaucoma treatment. Latanoprost has the most
RCTs and is the only prostaglandin analogue with RCTs over 12
months. Other research methodologies (i.e. observational
studies) have to be considered alongside RCTs to address impor-
tant clinical issues like long-term safety and disease progression.
There is a lack of RCT evidence to explore differential treatment-
effects among subgroups.
SENSORY SYSTEMS DISORDERS—Cost Studies
PSS5
MEDICAL COST OF GLAUCOMA IN SWEDEN
Ström O1, Buchholz P2,Walt JG3, Mesterton J1, Bengtsson B4,
Heijl A4
1i3 Innovus, Stockholm, Uppland, Sweden, 2Allergan Europe, Ettlingen,
Germany, 3Allergan Inc, Irvine, CA, USA, 4Malmo University Hospital,
Malmo, Sweden
OBJECTIVE: Glaucoma has been estimated to affect 2.1% of the
population aged 40 years and over and given the clinical impact
of glaucoma, it is important to evaluate the potential economic
burden of the disease. The aims were to estimate the direct
medical costs of glaucoma in Sweden and also to investigate the
hypothesized cost drivers; intraocular pressure (IOP), amount of
visual ﬁeld damage estimated by the MD, change of MD (ÄMD)
and pseudoexfoliation syndrome (PEX). METHODS: The study
was based on 583 Swedish patients with open-angle glaucoma
and manifest ﬁeld loss followed between 4.5 and 9.25 years.
Data on MD, IOP, PEX, medical resources, and low-vision centre
visits were collected and organized in three-month periods. The
average baseline MD was -11.7 dB and initial values of average
IOP, age were 22.5 mmHg, and 71 years, respectively. All used
resources were multiplied with its respective unit costs to calcu-
late the medical costs for each patient. Cost regressions were
estimated with a multivariate population-averaged panel data
model. RESULTS: Average annual medical cost/patient of glau-
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coma was estimated at €627/year. Independent cost drivers were
IOP (p < 0.001), MD (p < 0.001), ÄMD (p = 0.03) and PEX
(p < 0.001). Prevalence of PEX was associated with 21% higher
costs. Each one-unit increase in mmHg (IOP), decrease in dB
(MD) or ÄdB/year (ÄMD) increased costs by 2.9 %, 1.2% and
5.7%, respectively. Patients that had visited a low-vision centre at
least once had 46% higher annual costs than the average patient.
CONCLUSION: MD, ÄMD, IOP, and PEX are all drivers of
medical cost of glaucoma in Sweden. Further, the variables are
predicting cost independently of each other.
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OBJECTIVE: To assess the cost-effectiveness of intermittent vs.
continuous anti-TNF alpha therapies in chronic plaque psoriasis.
METHODS: An economic model was constructed to estimate
the cost per month in remission for intermittent etanercept 25 mg
twice weekly (biw) or 50 mg biw, continuous adalimumab or
continuous inﬂiximab compared with no systemic therapy
(NST). Patients considered had chronic plaque psoriasis with
both Psoriasis Area and Severity Index (PASI) and Dermatology
Life Quality Index (DLQI) > = 10 at baseline, and so would be
eligible for anti-TNF alpha treatment under UK guidelines.
Remission was deﬁned at patients experiencing an improvement
of at least 75% of their baseline PASI. Response rates were taken
from registration studies for each agent: maintenance of response
with continuous therapy and likelihood of response to intermit-
tent therapy were extrapolated from published studies to a time
horizon of ten years using a Markov process. Costs were
estimated from a UK payer perspective including drug cost,
administration visits and hospital stay for treatment failures.
RESULTS: Cost per month in remission for each therapy com-
pared with NST was estimated to be: GBP162 (95% CI: 93–287)
for etanercept 25 mg biw; GBP418 (337–531) for etanercept
50 mg biw; GBP1,867 (1,643–2,136) for inﬂiximab and GBP588
(452–804) for adalimumab. The cost-effectiveness ratios
for continuous therapies were sensitive to the criteria used for
withdrawal from treatment. The cost-effectiveness ratios for
intermittent therapy were sensitive to the duration of treatment
interruption achieved and response rate after therapy re-
introduction. All regimens were found to be particularly ap-
propriate in psoriasis patients with severe disease at baseline.
CONCLUSION: The model found intermittent treatment with
etanercept to be more efﬁcient than continuous treatment with
other anti-TNF alpha therapies, as it allows patients to be main-
tained in response at lower drug cost.
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OBJECTIVE: To evaluate the cost-effectiveness of ranibizumab
versus photodynamic therapy with verteporﬁn (PDT-V) and best
standard care (BSC) for the treatment of all wet age-related
macular degeneration (AMD) lesion subtypes (predominantly
classic (PC), minimally classic (MC) and occult lesions (OC)) in
Canada. METHODS: A ten-year Markov model with three-
month cycles was adapted to the Canadian setting to simulate the
evolution of visual acuity (VA) levels in subfoveal wet AMD
patients according to Canadian guidelines. Analyses were per-
formed from the perspective of the Ontario Ministry of Health
with each AMD subtype modeled separately. The initial distri-
bution of patients across VA levels followed the distribution
observed in MARINA and ANCHOR (sham controlled phase III
randomized multicentre clinical trials) at randomization. Transi-
tion probabilities were based on data from the same trials.
Treatment with 0.5 mg ranibizumab was assumed, with nine
injections in year 1 and six injections in year 2. Treatment dura-
tion was assumed to be one year for PC and two years for MC
and OC lesions. Five clinicians completed a resource use ques-
tionnaire from which therapy and adverse event costs were esti-
mated (2007 CDN$). Quality-of-life estimates were obtained
from a time trade-off study carried out in a sample of the UK
general population. Outcomes were measured in terms of
quality-adjusted-life-years (QALY) and discounted (along with
costs) at 5% annually. One-way and probabilistic sensitivity
analyses were performed to estimate uncertainty around incre-
mental cost-effectiveness ratios (ICER). RESULTS: Ranibizumab
demonstrated cost-effectiveness relative to PDT-V and BSC in all
lesion types assuming a $50,000 threshold. The ICER for PC
lesions was $4,167/QALY and $21,857/QALY relative to PDT-V
and BSC respectively. For MC and OC lesions the ICER was
$37,363/QALY and $38,151/QALY respectively relative to BSC.
CONCLUSION: Ranibizumab offers good value for money
compared to current standard treatments for all wet AMD lesion
types.
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OBJECTIVE: To compare cost-effectiveness of topical prostag-
landins for maintaining persistency during the ﬁrst 2 years after
initiating therapy. METHODS: Data derived from Ingenix
managed care database. Patients with latanoprost (LAT), bimato-
prost (BIM), travoprost (TRAV) dispensed between Janaury 1,
2004–December 31, 2004 screened for inclusion. Index
agent = ﬁrst agent ﬁlled; index date = ﬁll date. Patients excluded
if: < 40 years old; not continuously enrolled for 180 days before
index date; had any ocular hypotensive dispensed or no glau-
coma diagnosis within 180 days before index date. Data cen-
sored at the earliest of end of enrollment; end of study (December
31, 2005); or upon adding/switching to a new agent. Cox regres-
sion (adjusted for age, gender, recent diagnosis of preglaucoma/
ocular hypertension) used to compare relative risk of discon-
tinuation of initial prostaglandin and produce survival (on
therapy) plot over ﬁrst 720 treatment days for each prostaglan-
din. Area under survival curve used to estimate expected days on
therapy. RESULTS: A total of 9124 patients met inclusion crite-
ria (LAT, n = 5816; BIM, n = 1665; TRAV, n = 1643). Relative
risk of discontinuing index prostaglandin over ﬁrst 2 years was
8.3% higher for BIM (p = 0.016) and 24.4% higher for TRAV
(p < 0.001). Within the ﬁrst 720 days, expected days of uninter-
rupted, continuous therapy were estimated as 245 for LAT, 226
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